Clinical Trial: Short-term Efficacy and Safety of Abrocitinib 200 mg Combined with Topical Therapy in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study (China)

Posted On: 2026-09-25

China, Sept. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Short-term Efficacy and Safety of Abrocitinib 200 mg Combined with Topical Therapy in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133315

Registration Time: 2026/09/24

Type: Observational study

Primary Sponsor: The Fifth Affiliated Hospital, Sun Yat-sen University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=332763

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया हमे संपर्क करें.

विशेष

Category

Source

Publication

Location

Clinical Trial: Short-term Efficacy and Safety of Abrocitinib 200 mg Combined with Topical Therapy in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study (China)